Moffitt Presentations at ASH 2025

Note - all times are listed as EST

Friday, December 5

	Menin Masters for AML Care: Guidance on Integrating Menin Inhibitor Regimens & Boosting Efficacy in Challenging AML Subtypes Satellite Symposia David Sallman, MD 7:00-10:00am Valencia Room W415D
	Blood Buddies: Inclusion Pathways ASH-a-Palooza Melissa Alsina, MD 1:30-3:50pm SeaWorld BloodBuddies Pavillion
	Expert Second Opinion: Investigators Discuss the Optimal Management of Patients with Myelofibrosis and Systemic Mastocytosis Satellite Symposia Andrew Kuykendall, MD 3:00-6:00pm Hyatt Regency TUV
	Bridging the Gaps in CAR T-Cell Therapy for Hematological Malignancies: Expert Guidance, Clinical Experience and Increased Access Satellite Symposia Frederick Locke, MD 3:00-6:00pm W230

Saturday, December 6

	Predictors of early relapse following ciltacabtagene autoleucel: Informing risk-adapted therapy in relapsed/refractory multiple myeloma Oral Abstract Session 93 Doris Hansen, MD 10:00-10:15am West Hall D2
	Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study Oral Abstract Session 81 Andrew Kuykendall, MD 10:00-10:15am W414CD
	CAR-T efficacy in large B-cell lymphoma is shaped by neoantigen-driven epitope spreading and limited by HLA loss and genomic instability Oral Abstract Session 107 Constanza Savid-Frontera 10:30-10:45am Sunburst Room (W340)
	Adult BMT/Cellular Therapy Career Development Lunch Rawan Faramand, MD 11:15am Hyatt Windemere Ballroom
	Outcomes and characteristics of patients treated with frontline intensive chemotherapy versus hypomethylating agent/venetoclax-based therapy in DDX41-mutated Acute Myeloid Leukemia (AML) Oral Abstract Session 291 Fatima Tuz Zahra 2:30-2:45pm W415A
	Durability of complete response outperforms complete response rates as a surrogate endpoint for advancing to phase III trials in high-risk myelodysplastic syndromes Oral Abstract Session 240 Julie Braish 3:15-3:30pm Valencia Room W415BC
	No Shots Needed: Direct Oral Anticoagulants in Cancer-Associated Thrombosis – 10-Year Follow-Up Educational Program Michael Jaglal, MD 4:00-5:00pm West Hall D2
	Real-world outcomes of Y90-ibritumomab tiuxetan (Zevalin) in low-grade B-cell nonHodgkin lymphoma: A single-institution experience Poster Abstract Session 1825 Abida Babu 5:30-7:30pm West Halls B3-B4
	Treatment responses and survival of newly diagnosed older or unfit patients (pts) with IDH1/2-mutated Acute Myeloid Leukemia (AML): An analysis of the MARROW consortium Poster Abstract Session 1626 Onyee Chan, MD 5:30-7:30pm West Halls B3-B4
	Real-world efficacy outcomes of epcoritamab and glofitamab in Relapsed/Refractory aggressive B-cell lymphoma: A single-center cohort emphasizing trial-ineligible populations Poster Abstract Session 2767 Daniel DeAvila, M.S. 5:30-7:30pm West Halls B3-B4
	Cytopenias and infectious complications following CD19-directed CAR-T cell therapy in patients with B-ALL: A single-center retrospective analysis Poster Abstract Session 1580 Kriti Gera 5:30-7:30pm West Halls B3-B4
	Immune exhaustion limits CD19 CAR-T efficacy in Richter’s transformation Poster Abstract Session 1791 M. Bakri Hammami 5:30-7:30pm West Halls B3-B4
	Dermatologic adverse effects with elranatamab mimicking talquetamab Poster Abstract Session 2200 M. Bakri Hammami 5:30-7:30pm West Halls B3-B4
	Bridging therapy response and low pre-lymphodepletion plasma cell burden are associated with improved safety and efficacy outcomes of ciltacabtagene autoleucel in multiple myeloma Poster Abstract Session 2214 Doris Hansen, MD 5:30-7:30pm West Halls B3-B4
	Treatment related outcomes of very old (>85 years) diffuse large b-cell lymphoma patients Poster Abstract Session 1882 Sushmita Khadka, MD 5:30-7:30pm West Halls B3-B4
	The role of hypomethylating agents and venetoclax combination in higher risk myelodysplastic syndromes Poster Abstract Session 2072 Rami Komrokji, MD 5:30-7:30pm West Halls B3-B4
	Survival and clinical outcomes in patients with myelofibrosis and new or worsening anemia treated with ruxolitinib: A systematic review and meta-analysis Poster Abstract Session 2031 Andrew Kuykendall, MD 5:30-7:30pm West Halls B3-B4
	Additional myelodysplasia-related genes mutations affected the clinical presentations and prognosis of patients with SRSF2/TET2 co-mutations Poster Abstract Session 2069 Michael Martin 5:30-7:30pm West Halls B3-B4
	Impact of radiation in limited stage diffuse large B-cell lymphoma in the modern era Poster Abstract Session 1896 Juan Ramirez, MD 5:30-7:30pm West Halls B3-B4
	Survival outcomes in therapy-related acute lymphoblastic leukemia: A population-based analysis from SEER (2000–2022) Poster Abstract Session 1560 Anish Shah, MD 5:30-7:30pm West Halls B3-B4
	Preemptive Rituximab in patients with ADAMTS13 relapse in thrombotic thrombocytopenic purpura: A systematic review Poster Abstract Session 1333 Moazzam Shahzad, MD 5:30-7:30pm West Halls B3-B4
	Outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis using posttransplant cyclophosphamide-based gvhd prophylaxis Poster Abstract Session 2460 Moazzam Shahzad, MD 5:30-7:30pm West Halls B3-B4
	Atypical hemolytic uremic Syndrome Triggered by malignancy and drug exposure: A systematic review and meta-analysis Poster Abstract Session 2689 Moazzam Shahzad, MD 5:30-7:30pm West Halls B3-B4
	Optimal dose and duration of venetoclax for induction therapy in acute myeloid leukemia and myelodysplastic syndrome: A systematic review and meta-analysis Poster Abstract Session 2831 Moazzam Shahzad, MD 5:30-7:30pm West Halls B3-B4
	Trial in progress: A phase I/ib dose-finding study of ropeginterferon alfa-2b (P1101) in patients with cutaneous T-cell lymphoma (CTCL) Poster Abstract Session 1881 Yumeng 'Julia' Zhang, MD 5:30-7:30pm West Halls B3-B4

Sunday, December 7

	Demystifying the Diagnosis and Management of ICUS, CHIP, and CCUS Education Program Zoey Xie, MD 9:30-9:50am Hyatt Regency Ballroom OPQ
	JOINT SESSION: Game of Clones – The Evolution of Hematopoiesis from Birth to Aging Scientific Program Nancy Gillis Johnson, PharmD, PhD 9:30-11:05am W312
	A phase 2 study of canakinumab in patient with myelofibrosis: Results from part 1 Oral Abstract Session 483 Andrew Kuykendall, MD 10:00-10:15am W414AB
	Nfkb signaling in idecabtagene vicleucel infusion product drives response in relapsed/refractory multiple myeloma Oral Abstract Session 504 Jerald Noble 10:45-11:00am Sunburst Room (W340)
	Setting the stage in KMT2A rearranged acute myelogenous leukemia in the era of menin inhibitors Poster Abstract Session 3393 Omar Alzarkali 6:00-8:00pm West Halls B3-B4
	Clinical and genomic landscape of STAT5B mutations in lymphoid and myeloid malignancies Poster Abstract Session 3531 Fnu Amisha 6:00-8:00pm West Halls B3-B4
	Investigating the clonal and biological underpinnings of systemic mastocytosis with an associated hematological neoplasm Poster Abstract Session 3763 Nana Adjoa Ben-Crentsil 6:00-8:00pm West Halls B3-B4
	Outcomes of elderly (≥ 70) Acute Myeloid Leukemia (AML) patients receiving continued hypomethylating agent/venetoclax (HMA/VEN) versus allogeneic hematopoietic cell transplantation (HCT) Poster Abstract Session 4300 Onyee Chan, MD 6:00-8:00pm West Halls B3-B4
	Machine learning using bayesian networks to predict response in patients with newly diagnosed Acute Myeloid Leukemia Poster Abstract Session 4357 Onyee Chan, MD 6:00-8:00pm West Halls B3-B4
	Indirect treatment comparison (ITC) of asciminib and dasatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) Poster Abstract Session 4611 Onyee Chan, MD 6:00-8:00pm West Halls B3-B4
	Delta opiod receptor signaling modulates myeloid suppression in Myelodysplastic Syndromes Poster Abstract Session 3841 Erika Eksioglu, PhD 6:00-8:00pm West Halls B3-B4
	Trial in progress: QUINTESSENTIAL—a phase 2 study of arlocabtagene autoleucel (arlo-cel) in patients with relapsed/refractory multiple myeloma (RRMM) Poster Abstract Session 4079 Ciara Freeman, MD, PhD 6:00-8:00pm West Halls B3-B4
	Real world outcomes of asciminib in relapsed/refractory Philadelphia chromosome positive B-ALL and blast Phase CML Poster Abstract Session 2257 Kriti Gera 6:00-8:00pm West Halls B3-B4
	Clinical, genetic, and pathologic differences across race, ethnicity, and sex in patients with MDS and precursor conditions from the national MDS natural history study Poster Abstract Session 3845 Nancy Gillis Johnson, PharmD, PhD 6:00-8:00pm West Halls B3-B4
	Optimizing immunity to pneumococcus by vaccination with pneumococcal 13-valent conjugate vaccine before and after CD19-targeted CAR T cell immunotherapy Poster Abstract Session 4166 M. Bakri Hammami 6:00-8:00pm West Halls B3-B4
	Real-world incidence and management of non-icans neurologic events following ciltacabtagene autoleucel in multiple myeloma Poster Abstract Session 4596 Doris Hansen, MD 6:00-8:00pm West Halls B3-B4
	Outcomes of hypomethylating agent (HMA)-based therapy in patients with myelodysplastic syndrome with fibrosis Poster Abstract Session 3853 Abigail Huetteman 6:00-8:00pm West Halls B3-B4
	Early real-world experience with revumenib outside of a clinical trial setting: A single center retrospective review of efficacy and tolerability Poster Abstract Session 3448 Umar Iqbal 6:00-8:00pm West Halls B3-B4
	Racial disparities in genomic alterations and survival outcomes in Acute Myeloid Leukemia (AML) Poster Abstract Session 4630 Utsav Joshi 6:00-8:00pm West Halls B3-B4
	IDH mutant MDS: Proposal for disease subset recognition based on molecular and clinical features, and the availability of targeted therapies Poster Abstract Session 3851 Rami Komrokji, MD 6:00-8:00pm West Halls B3-B4
	Elevated serum erythropoietin level is associated with unique clinical and genomic features, response to treatment, and outcomes in lower-risk myelodysplastic syndromes Poster Abstract Session 3856 Zena Komrokji 6:00-8:00pm West Halls B3-B4
	Comparative immune profiling reveals T-cell exhaustion in EBV+ monomorphic PTLD vs. immunocompetent DLBCL Poster Abstract Session 3568 Aleksandr Lazaryan, MD, MPH, PhD 6:00-8:00pm West Halls B3-B4
	Estimating the survival impact of not receiving CAR T-cell (CAR T) therapy when eligible in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in the United States (US) Poster Abstract Session 4510 Frederick Locke, MD 6:00-8:00pm West Halls B3-B4
	Interim Results of the CMML scrna-seq atlas: GMP skewing is independently associated with overall survival in CMML Poster Abstract Session 3840 Amy McLemore 6:00-8:00pm West Halls B3-B4
	Real-world outcomes of talquetamab in Relapsed/Refractory multiple myeloma Poster Abstract Session 4051 Karun Neupane, MD 6:00-8:00pm West Halls B3-B4
	Heterogeneity of circulating CD57+ cytotoxic cell subsets across disease stage and aggressiveness in cutaneous T cell lymphoma Poster Abstract Session 3644 Sara Niyazi, DO 6:00-8:00pm West Halls B3-B4
	Identifying splice variants of cell surface proteins for chimeric antigen receptor T cell therapy of Acute Myeloid Leukemia Poster Abstract Session 4119 Fabiana Perna, MD, PhD 6:00-8:00pm West Halls B3-B4
	Mapping out the impact of MAP kinase in primary myelofibrosis Poster Abstract Session 3812 Samuel Reynolds, MD 6:00-8:00pm West Halls B3-B4
	Predictors of outcomes to allogeneic hematopoietic cell transplantation (allo-HCT) for TP53 mutant myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML) patients and impact of hypomethylating agent (HMA) maintenance therapy Poster Session Abstract 4291 David Sallman, MD 6:00-8:00pm West Halls B3-B4
	Phase 2 study of brexu-cel in minimal residual disease positive B-cell acute lymphoblastic leukemia Poster Abstract Session 3359 Bijal Shah, MD 6:00-8:00pm West Halls B3-B4
	Impact of early bacteremia on clinical outcomes following allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide-based gvhd prophylaxis Poster Abstract Session 4200 Moazzam Shahzad, MD 6:00-8:00pm West Halls B3-B4
	Factors associated with acute and chronic graft-versus-host disease after unrelated donor hematopoietic cell transplantation using posttransplant cyclophosphamide-based GVHD prophylaxis Poster Abstract Session 4254 Moazzam Shahzad, MD 6:00-8:00pm West Halls B3-B4
	Not so exclusive: Co-mutations in JAK2, MPL and CALR define distinct hematologic and clonal signatures Poster Abstract Session 3815 Ekrem Turk 6:00-8:00pm West Halls B3-B4
	Real-world survival outcomes following allogeneic hematopoietic cell transplantation in peripheral T-cell lymphomas: A Florida multi-institutional cohort study Poster Abstract Session 4537 Fatima Tuz Zahra 6:00-8:00pm West Halls B3-B4
	Outcomes of CD20xCD3 bispecific antibody therapy as holding or bridging therapy prior to chimeric antigen receptor T-cell infusion in aggressive B-cell lymphomas Poster Abstract Session 4555 Fatima Tuz Zahra 6:00-8:00pm West Halls B3-B4
	Prospera (ABNL-MARRO 002): A randomized phase 2 study of pacritinib vs. hydroxyurea in patients with advanced proliferative chronic myelomonocytic leukemia (CMML) Poster Abstract Session 3873 Zhuoer 'Zoey' Xie, MD, MS 6:00-8:00pm West Halls B3-B4

Monday, December 8

	CAR T-cell and Bispecific Antibodies in the Management of Multiple Myeloma Educational Session Doris Hansen, MD 10:30-10:50am West Hall D2
	Interim Results of the CMML intercept study: A prospective observational study to evaluate the role of acute inflammation in CMML disease progression Oral Abstract Session 788 Zhuoer 'Zoey' Xie, MD, MS 10:45-11:00am W415A
	Beyond chip: Ccrs predicts prolonged cytopenias and inferior survival following anti-BCMA CAR-T in multiple myeloma Oral Abstract Session 930 Zhuoer 'Zoey' Xie, MD, MS 4:00-4:15pm Sunburst Room (W340)
	Developing SEMA4A-directed CAR t cells to overcome low BCMA antigen density in multiple myeloma Poster Abstract Session 6100 Francesca Albano 6:00-8:00pm West Halls B3-B4
	Feasibility and safety of accelerated glofitamab step-up in rapidly progressive relapsed/refractory diffuse large B-cell lymphoma: A real-world single center experience Poster Abstract Session 5512 Fnu Amisha 6:00-8:00pm West Halls B3-B4
	Refined elderly comorbidity index is highly predictive of post-transplant survival in older adults with Acute Myeloid Leukemia and myelodysplastic syndrome Poster Abstract Session 6076 Fnu Amisha 6:00-8:00pm West Halls B3-B4
	Phase 1/1b dose escalation and expansion of CPX-351 in combination with gemtuzumab ozogamicin in newly diagnosed Acute Myeloid Leukemia (AML) Poster Abstract Session 5216 Onyee Chan, MD 6:00-8:00pm West Halls B3-B4
	Artificial intelligence-based diagnosis of myelodysplastic syndromes/neoplasms using bone marrow Poster Abstract Session 5642 Palak Dave 6:00-8:00pm West Halls B3-B4
	Real-time multimodal AI outperforms conventional scores for early risk prediction in BCMA CAR-T–Treated myeloma Poster Abstract Session 6140 Ciara Freeman, MD 6:00-8:00pm West Halls B3-B4
	Impact of autoimmune disease on outcomes after BCMA-directed CAR-T cell therapy for patients with multiple myeloma Poster Abstract Session 6362 Laith Hamed 6:00-8:00pm West Halls B3-B4
	Journey of relapsed or refractory multiple myeloma (RRMM) after quadruple-class exposure (QCEx): Poor outcomes and high attrition Poster Abstract Session 5771 Doris Hansen, MD 6:00-8:00pm West Halls B3-B4
	Impact of pre-existing central nervous system conditions and cognitive impairments on toxicity and outcomes after BCMA-directed CAR-T cell therapy Poster Abstract Session 6370 Syed Hussain 6:00-8:00pm West Halls B3-B4
	Impact of pre-existing psychiatric conditions on toxicity and outcomes of patients after BCMA-directed CAR-T cell therapy Poster Abstract Session 6371 Syed Hussain 6:00-8:00pm West Halls B3-B4
	ClonoSEQ MRD negativity at day 90 is a strong predictor for progression-free and overall survival after BCMA-directed CAR T-cell therapy for relapsed multiple myeloma Poster Abstract Session 5846 Brandon Kale 6:00-8:00pm West Halls B3-B4
	An independent, multi-center analysis of the post-approval utilization and efficacy of pacritinib and momelotinib in patients with myelofibrosis Poster Abstract Session 5600 Andrew Kuykendall, MD 6:00-8:00pm West Halls B3-B4
	Humanin-like 8 regulates metabolic fitness and anti-apoptotic programming in CD19 CAR-T cells Poster Abstract Session 5906 Samira Naderinezhad 6:00-8:00pm West Halls B3-B4
	Direct small molecule inhibition of RAS enhances JAK2 inhibitor therapy in preclinical models of myeloproliferative neoplasms Poster Abstract Session 5533 Garima Pandey, PhD 6:00-8:00pm West Halls B3-B4
	Persistent racial disparities in Sézary syndrome outcomes despite use of modern therapies: A single-center analysis Poster Abstract Session 5247 Lalith Roopesh 6:00-8:00pm West Halls B3-B4
	Dynamic changes in the bone marrow niche following CD19-targeted CAR-T cell infusion in diffuse large B cell lymphoma (DLBCL) Poster Abstract Session 5881 Timothy Shaw, PhD 6:00-8:00pm West Halls B3-B4
	Evolution of t(11;14) biology in multiple myeloma and it’s role on outcomes to venetoclax treatment Poster Abstract Session 5730 Praneeth Reddy Sudalagunta 6:00-8:00pm West Halls B3-B4
	Balancing the treatment outcomes: Survival and quality of life among older adults with AML Poster Abstract Session 6405 Sara Tinsley-Vance, PhD 6:00-8:00pm West Halls B3-B4
	Real-world outcomes of elranatamab in relapsed/refreactor multiple myeloma: A single center analysis Poster Abstract Session 5833 Corbin Wright, MD 6:00-8:00pm West Halls B3-B4
	Impact of clonal hematopoiesis on hematologic recovery and outcomes following tumorinfiltrating lymphocyte therapy Poster Abstract Session 5932 Zhuoer 'Zoey' Xie, MD 6:00-8:00pm West Halls B3-B4

Moffitt Presentations at ASH 2025

Note - all times are listed as EST

Cambiar el idioma